Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tegavivint - Apollomics/Iterion Therapeutics

Next Previous
X
Search
Drug Profile

Tegavivint - Apollomics/Iterion Therapeutics

Alternative Names: APL-121; BC-2059; Tegatrabetan - Iterion therapeutics

Latest Information Update: 28 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BetaCat Pharmaceuticals
  • Developer Apollomics; Iterion Therapeutics; M. D. Anderson Cancer Center; Ohio State University Comprehensive Cancer Center
  • Class Anthracenes; Antineoplastics; Hydroxylamines; Nitroso compounds; Piperidines; Small molecules; Sulfonamides
  • Mechanism of Action Beta catenin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibroma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fibroma
  • Phase I/II Liver cancer; Solid tumours
  • Phase I Acute myeloid leukaemia; B-cell lymphoma; Non-small cell lung cancer
  • Preclinical Lymphoma; Osteosarcoma
  • No development reported Multiple myeloma

Most Recent Events

  • 13 Sep 2023 Phase-I/II clinical trials in Liver cancer (Late-stage disease, Second-line therapy or greater, Combination therapy) in Canada, USA (IV) (NCT05797805)
  • 13 Sep 2023 Phase-I/II clinical trials in Liver cancer (Late-stage disease, Second-line therapy or greater, Monotherapy) in Canada, USA (IV) (NCT05797805)
  • 28 Aug 2023 No recent reports of development identified for phase-I development in Fibroma(Inoperable/Unresectable, Recurrent, Second-line therapy or greater) in Canada (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top